The use of the nutriceutical "PROfertil" as a therapy of the "Male factors", for the improvement of semen quality

M. Imhof
Medical University of Vienna, AKH
Department of Gynecology and Obstetrics

Introduction:
 
The reason for infertility may be ascribed equally to both men ("male" factor) and women ("female" factor). There has been a steady rise during the last decade concerning the number of pathologic spermiograms. Until today there is no proven therapy for the improvement of semen quality.
 
The goal of this study is to administer a combination product comprising 8 substances, which are all known to improve semen quality. The hypothesis is that the effect of the single substances accumulate and therefore ensure a stronger response. The study collective contains 120 men, on average 36.2 years old, with a long lasting child wish ( > 2 years) and at least 2 pathologic spermiograms in their anamnesis. Patients with azoospermia, aspermia, varicosis of the testes and urogenital infections were excluded. The patients took PROfertil^® 2 capsules a day for the duration of 3 months. After the time period of 3 month a control spermiogram was performed.

 
Results:
 
The sperm cell density increased from an average of 29.46 Mill/ml to 53.19 Mill/ml (+ 80,54 %). The average gain of the spermatocyt count per milliliter was 23.73 million. The number of progressive motile spermatocytes increased on average from 8.95 % to 19.27 % (+115.3 %). The total motility increased cumulatively from 33.13 % to 49.27 % (+ 48.71 %). The number of morphologically normal spermatocytes was ameliorated from 31.14 % to 38.90 % (+24.91 %). The ejaculation volume increased from 2.91 to 3.61 ml (+ 24.05 %).
 
 
Summary:
 
At the conclusion of this study, 30 out of 120 test persons had spermiograms with normal results (normozoospermia). To date 21 pregnancies were reported. These results support the assumption that the combined use of the substances, which are known to improve semen quality, works significantly better than using the substances separately.

Source: Data on File, Lenus Pharma